MedTrace Logo

A Follow-up Study for a Phase III, Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine

NCT02001233 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10077

Last updated 2022-05-26

No results posted yet for this study

Summary

The purpose of this follow-up study is to evaluate the two-year efficacy, immunogenicity and safety of EV71 Vaccines in preventing Hand, Foot and Mouth disease caused by EV71 in a total 10,000 healthy infants volunteers aged from 6 to 35months old.

Conditions

  • Hand, Foot and Mouth Disease

Interventions

BIOLOGICAL

EV71 vaccine

inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval

Sponsors & Collaborators

  • Sinovac Biotech Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Feng-Cai Zhu, BS · Jiangsu Center for Diseases Control and Prevention

Eligibility

Min Age
6 Months
Max Age
35 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-03-31
Completion
2014-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02001233 on ClinicalTrials.gov